Key result
Transcatheter valve-in-valve implantation with the Edwards SAPIEN valve in 5 high-risk patients with degenerated bioprostheses achieved 100% procedural success and no mortality at 6 months.
Why the study?
Does transcatheter valve-in-valve implantation improve clinical and echocardiographic outcomes in high-surgical-risk patients with degenerated bioprosthetic valves?
Case Report (n=5)
No
Does transcatheter valve-in-valve implantation improve clinical and echocardiographic outcomes in high-surgical-risk patients with degenerated bioprosthetic valves?
Transcatheter valve-in-valve implantation using the Edwards SAPIEN valve is a feasible and safe alternative to redo surgery for high-risk patients with degenerated bioprosthetic valves in various positions.
Answers are grounded in this paper and cite their sources.
ViV may be feasible across positions in high-risk patients; hypothesis-generating and should not yet change practice.
Introduction: After early successful experience with transcatheter aortic valve replacement (TAVR), concept of transcatheter implantation of a new valve within a failing bioprosthetic valve emerged. Valve-in-valve (ViV) implantation seems to be a simpler option for high risk surgical patients. Methods: We performed five ViV procedures in different valve positions. We included patients with failing bioprosthetic valves with high surgical risk due to concomitant comorbidities. We performed 2 transapical ViV procedures for failing mitral bioprosthetic valves, 1 transfemoral procedure for failing pulmonary valve and 2 transfemoral ViV implantation for failing tricuspid bioprosthetic valves. Results: The procedures were successfully completed in all 5 cases with initial excellent fluoroscopic and echocardiographic verification. There was no valve embolization or paravalvular leakage in any of the cases. Transcatheter valve function was appropriate with echocardiography. Post procedural clinical adverse events like pleural effusion and transient ischemic attack were managed successfully. In midterm follow up all cases remained in appropriate functional class except from the transcatheter pulmonary valve which became moderately stenotic and regurgitant. Conclusion: As the first Iranian all-comers case series with midterm follow up for ViV implantation, we had no mortality. Interestingly none of our patients had neurologic sequelae after the procedure. Midterm follow up for our patients was acceptable with good functional class and appropriate echocardiographic findings. Due to high surgical risk of the redo procedure after failing of a bioprosthetic valve especially in elderly patients with comorbidities, ViV implantation would be a good alternative to surgery for this high risk group.
No takes yet. Share an insight, caveat, or question.
Zeinali et al. (2017) conducted a case report in Degenerated bioprosthetic valves (n=5). Transcatheter valve-in-valve (ViV) implantation with Edwards SAPIEN valve was evaluated on Procedural success and mortality. Transcatheter valve-in-valve implantation with the Edwards SAPIEN valve in 5 high-risk patients with degenerated bioprostheses achieved 100% procedural success and no mortality at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: